Focal Laser Photocoagulation for Central Serous Chorioretinopathy in Under-Represented Populations: A Retrospective Case Series

Abstract

This case series examines visual and anatomic outcomes of focal laser photocoagulation in the treatment of central serous chorioretinopathy (CSCR) with subretinal fluid (SRF) in under-represented populations. We reviewed records of 25 eyes with CSCR and SRF that underwent focal laser photocoagulation. Visual acuity (VA) and central macular thickness (CMT) were recorded prior to laser, after laser treatment, and at final follow-up and were all compared using Wilcox signed-rank tests after using Shapiro-Wilk tests to determine normality. The racial and ethnic breakdown of our cohort (<i>n</i> = 25) includes 64% Hispanic (<i>n</i> = 16), 20% black (<i>n</i> = 5), 12% Asian (<i>n</i> = 3), 4% other (<i>n</i> = 1). Patients were followed for a median of 15.5 months (range: 5.75–87 months) after treatment. The VA prior to laser compared to best-available VA significantly improved (<i>p</i> = 0.0003). Pre-laser CMT to post-laser CMT (<i>p</i> &lt; 0.0001) and pre-laser CMT to final CMT (<i>p</i> &lt; 0.0001) significantly improved. Excluding the one eye that developed a choroidal neovascular membrane, the pre-laser VA to final VA improved significantly (<i>p</i> = 0.0047) as well as the pre-laser CMT to final CMT (<i>p</i> &lt; 0.0001). Of the 25 eyes, 4 had persistent SRF following laser, and of the 21 eyes with complete resolution of SRF, 2 developed recurrent SRF. Focal laser photocoagulation can significantly improve VA and CMT in CSCR with active SRF in patients who have been under-represented in prior clinical studies.